<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The glycine site, <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> 5-<z:chebi fb="13" ids="29785">nitro</z:chebi>-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione (ACEA1021) was previously tested only in models of transient <z:hpo ids='HP_0001297'>stroke</z:hpo> with pre-treatment paradigms </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore tested whether it would protect in two models of permanent <z:hpo ids='HP_0001297'>stroke</z:hpo> in two rat strains with delayed treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Intravenous ACEA1021 reduced <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> by 62% (15 min treatment delay) and 42% (2 h treatment delay), relative to vehicle-injected rats, when subjected to a modified Tamura and permanent intraluminal filament model of <z:hpo ids='HP_0001297'>stroke</z:hpo>, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In comparison, intravenous <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> (500 mg/kg), which was tested in separate animal cohorts, had no significant effect on infarction </plain></SENT>
<SENT sid="4" pm="."><plain>These data show that ACEA1021 protects against permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, even with a 2 h post-treatment delay </plain></SENT>
<SENT sid="5" pm="."><plain>Characterization of the therapeutic window with longer outcome times including infarction and neurobehavioral endpoints is needed </plain></SENT>
</text></document>